Kinnov Therapeutics
First-in-class therapy for a worldwide market
Menu
Company
Alcohol addiction
R&D / Pipeline
Product KT-110
Partners / Investors
Business strategy
News
Contact us
Final approval by ANSM of Phase 2 study of KT-110 on alcohol addiction
←
Emmanuel de RIVOIRE appointed General Manager of KT
Kinnov Therapeutics raised 2.5 M€ for Phase 2 study of KT-110 on alcohol addiction
→